<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Fuerst Ittleman &#187; General</title>
	<atom:link href="http://www.fuerstlaw.com/wp/index.php/category/general/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.fuerstlaw.com/wp</link>
	<description>Fuerst Ittleman Law Firm</description>
	<lastBuildDate>Fri, 03 Feb 2012 21:47:24 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Sackett v. EPA Highlights The Ongoing Debate Over What Actions Are “Final Agency Actions”</title>
		<link>http://www.fuerstlaw.com/wp/index.php/31/sackett-v-epa-highlights-the-ongoing-debate-over-what-actions-are-final-agency-actions/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/31/sackett-v-epa-highlights-the-ongoing-debate-over-what-actions-are-final-agency-actions/#comments</comments>
		<pubDate>Tue, 31 Jan 2012 14:44:12 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[General]]></category>
		<category><![CDATA[Litigation]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=1686</guid>
		<description><![CDATA[On January 9, 2012, the Supreme  Court heard oral argument in the case of Sackett  v. United States Environmental Protection Agency. Although the facts of the  case concern issues governed by the Clean Water Act (“CWA”), this case is  important to all administrative law practitioners because of its potential to  [...]]]></description>
			<content:encoded><![CDATA[<p>On January 9, 2012, the Supreme  Court heard oral argument in the case of <em>Sackett  v. United States Environmental Protection Agency</em>. Although the facts of the  case concern issues governed by the Clean Water Act (“CWA”), this case is  important to all administrative law practitioners because of its potential to  more clearly define the line between “final agency action,” which is generally  subject to judicial review, and non-final agency actions which are not. Such a  clarification will not only serve as a guide in future litigation against  federal administrative agencies, but may also dramatically change how such  agencies engage in “informal” communications with those subject to their  jurisdiction. A copy of the oral argument transcript can be read <a href="http://www.supremecourt.gov/oral_arguments/argument_transcripts/10-1062.pdf" target="_blank"><strong>here.</strong></a></p>
<ol start="1" type="I">
<li><u>Background</u></li>
</ol>
<p>The  Sacketts’ fight with the EPA centers on a small 0.63 acre property located near  Priest Lake, Idaho and an EPA compliance order prohibiting its development. In  May of 2007, the Sacketts began to fill in the property with dirt and rocks in  preparation for construction of a three-bedroom home. However, in November of  that year, the EPA issued a Compliance Order that ordered construction to be  halted claiming that the Sacketts’ land was a wetland, was subject to EPA  jurisdiction under the CWA, and that the construction could not continue  without first obtaining a permit from the Army Corp of Engineers. The  Compliance Order also required the Sacketts to remove all fill material,  restore the property to its original condition, and replant the property with  wetland vegetation no later than April 30, 2008. Additionally, the Compliance  Order threatened civil penalties as high a $32,500 per day for each day the Sacketts did not comply with the Order. A  copy of the EPA’s news release announcing the issuance of the Compliance Order  can be read <a href="http://yosemite.epa.gov/opa/admpress.nsf/0/9301d59d2c957451852573a9006365cb?OpenDocument" target="_blank"><strong>here.</strong></a></p>
<ol start="2" type="I">
<li><u>What       is a Compliance Order?</u></li>
</ol>
<p>Under  the CWA, <em>after </em>the EPA identifies a  violation, the agency has three options: 1) the EPA may assess an  administrative penalty, in response to which “the alleged violator is entitled  to a reasonable opportunity to be heard and to present evidence, the public is  entitled to comment, and any assessed penalty is subject to immediate judicial  review;” 2) the agency can initiate a civil enforcement action in federal  district court; or 3) the EPA can issue, as it did in this case, an  administrative compliance order. <em>See Sackett  v. United States Environmental Protection Agency</em>, 622 F.3d 1139, 1142 (9th  Cir. 2010); <em>see generally </em><a href="http://www.law.cornell.edu/uscode/usc_sec_33_00001319----000-.html" target="_blank"><strong>33 U.S.C. § 1319</strong></a>.  As explained by the Ninth Circuit, “a compliance order is a document served on  [a] violator, setting forth the nature of the violation and specifying a time  for compliance with the [CWA].” <em>Sackett</em>,  622 F.3d at 1142. </p>
<p>In  order for a compliance order to be enforced, the agency must bring an  enforcement action against the individual in federal court. However, <em>pre-enforcement</em>, the CWA does not give  the alleged violator any right to a hearing in front of the agency to challenge  its issuance, nor does it allow for the alleged violator to sue the agency in  court. Instead, an alleged violator’s only way to challenge a compliance order  is to do nothing, face potential mounting fines, wait for the EPA to sue for  enforcement of the compliance order, and then argue the jurisdictional merits  of the EPA’s authority. It is this lack of a pre-enforcement challenge to EPA’s  authority which is at the heart of the Sacketts’ Supreme Court case.</p>
<ol start="3" type="I">
<li><u>Final       Agency Action and Review Under the Administrative Procedure Act</u></li>
</ol>
<p>Section  10(c) of the Administrative Procedure Act (“APA”), codified at <a href="http://www.law.cornell.edu/uscode/usc_sec_05_00000704----000-.html" target="_blank"><strong>5 U.S.C. § 704</strong></a>,  provides that “final agency action for which there is no other adequate remedy  in a court [is] subject to judicial review” under the APA. The APA applies to  all final agency actions except to the extent that an enabling statute  precludes review. <em>See </em><a href="http://www.law.cornell.edu/uscode/usc_sec_05_00000701----000-.html" target="_blank"><strong>5 U.S.C. § 701</strong></a>.  However, the statute provides that the judicial review provisions of the APA  may not be superseded by subsequent statutes unless such statutes expressly  provide so. <em>See</em> <a href="http://www.law.cornell.edu/uscode/usc_sec_05_00000559----000-.html" target="_blank"><strong>5 U.S.C. § 559</strong></a>.  Additionally, the Supreme Court has found that there is a presumption favoring  judicial review of administrative actions. <em>Abbott  Laboratories v. Gardner</em>, 387 U.S. 136, 140 (1967) overruled on other  grounds by <em>Califano v. Sanders</em>, 430  U.S. 99 (1977). However, this presumption is overcome “whenever the  congressional intent to preclude judicial review is fairly discernible in the  statutory scheme.” <em>Block v. Cmty.  Nutrition Inst.</em>, 467 U.S. 340, 351 (1984).</p>
<p>“The cases dealing with judicial review of administrative  actions have interpreted the ‘finality’ element in a pragmatic way.” <em><a href="http://supreme.justia.com/cases/federal/us/387/136/case.html" target="_blank"><strong>Abbott Laboratories</strong></a></em>,  387 U.S. at 149. As first announced in<em> Abbott  Laboratories,</em> an agency action will be considered final and a  pre-enforcement challenge will be allowed:</p>
<blockquote>
<p>Where the legal  issue presented is fit for judicial resolution, and where a regulation requires  an immediate and significant change in the plaintiffs conduct of their affairs  with serious penalties attached to noncompliance, access to the courts under  the [APA] and the Declaratory Judgment Act must be permitted, absent a  statutory bar or some other unusual circumstance. . . .</p>
</blockquote>
<p><em>Abbott Laboratories</em>, 387 U.S. at 153. </p>
<p>In <em><a href="http://supreme.justia.com/cases/federal/us/520/154/case.html" target="_blank"><strong>Bennett v. Spear</strong><strong>,  520 U.S. 154, 177-178 (1997)</strong></a></em>, the Court articulated a two  part test to determine whether an agency action qualifies as “final” and thus  generally subject to judicial review under the APA. As stated by the Court: </p>
<blockquote>
<p>As a general  matter, two conditions must be satisfied for agency action to be “final”: </p>
<p>    First, the action must mark the ‘<strong>consummation</strong>’ of the agency’s decision-making  process – it must not be of a merely tentative or interlocutory nature. </p>
<p>    And second, the action must be one  by which ‘<strong>rights or obligations have  been determined</strong>,’ or from which ‘<strong>legal  consequences will flow</strong>.’</p>
</blockquote>
<p><em>Bennett</em>, 520 U.S. at 177-178 (emphasis added). </p>
<p>When  assessing whether an agency action qualifies as “final,” the Court looks to  numerous factors including: 1) whether the administrative order provides the  definitive statement of the agency’s position; 2) whether the administrative  order has a “direct and immediate effect on the day-to-day business of the  complaining parties;” 3) whether agency expects immediate compliance with the  terms of the order such that the order has “the status of law;” 4) whether the  suit challenging the agency action presents a “legal issue fit for judicial  review;” and 5) whether the suit challenging the administrative order is  calculated to speed enforcement.” <em>See</em> <a href="http://www.americanbar.org/content/dam/aba/publishing/previewbriefs/Other_Brief_Updates/10-1062_petitioner.authcheckdam.pdf" target="_blank"><strong>Brief of the American  Farm Bureau Federation et al. as Amici Curiae Supporting Petitioners</strong></a>, <em>Sackett v. Environmental Protection  Agency</em>, 14-15 (No. 10-1062) (2012) (quoting <em>FTC v. Standard Oil Co. of California</em>, 449 U.S. 232, 239 (1980)).</p>
<ol start="4" type="I">
<li><u>The       Case Below</u></li>
</ol>
<p>In  this case, in response to the compliance order issued by the EPA, the Sacketts  sought an administrative hearing to challenge the EPA’s findings that the  property is subject to the CWA.<a href="#_ftn3" name="_ftnref3" title="" id="_ftnref3"> </a> However, this request was denied by the EPA. The Sacketts then filed their suit  before the United States District Court for the District of Idaho seeking  injunctive and declaratory relief arguing: 1) the compliance order was  arbitrary and capricious under the APA, <a href="http://www.law.cornell.edu/uscode/usc_sec_05_00000706----000-.html" target="_blank"><strong>5 U.S.C. § 706(2)(A)</strong></a>;  2) the order violated the Sacketts’ due process rights because it was issued  without a hearing; and 3) the standard for issuance of a compliance order under  the CWA was unconstitutionally vague. <em>Sackett</em>,  622 F.3d at 1141.</p>
<p>Both  the District Court and the Ninth Circuit dismissed the Sacketts’  pre-enforcement suit challenging the EPA’s issuance of the compliance order for  lack of subject-matter jurisdiction. In its opinion, the Ninth Circuit ruled  that, based upon the structure and objectives of the statutory scheme as well  as the legislative history of the CWA, the CWA precluded judicial review of  pre-enforcement actions under the APA. <em>Sackett</em>,  622 F.3d at 1143-1147. </p>
<p>The  Ninth Circuit additionally held that, although due process is violated when the  “practical effect of coercive penalties for noncompliance is to foreclose all  access to the courts so that compliance is sufficiently onerous and coercive penalties  sufficiently potent that a constitutionally intolerable choice might be  presented,” the statutory preclusion of pre-enforcement review of compliance  orders does not rise to such a level for two reasons. First, the CWA provides  for a permitting process, the denial of which is immediately reviewable in  federal district court under the APA. The Ninth Circuit found that the  jurisdiction issues raised by the Sacketts could be litigated in that forum. As  such, “rather than completely foreclosing the Sacketts’ ability to . . .  challenge CWA jurisdiction, the CWA channels judicial review through the  affirmative permitting process.” <em>Sackett</em>,  622 F.3d at 1146. Second, the Ninth Circuit held that, although the violation  of the CWA and of a issued compliance order may amount to [$37,500] each per  day, the civil penalty is a matter of judicial, not agency, discretion. Thus,  “any penalty ultimately assessed against the Sacketts would therefore reflect a  discretionary, judicially determined penalty, taking into account a wide range  of . . . equitable factors, and imposed only after the Sacketts have had a full  and fair opportunity to present their case in a judicial forum.” <em>Id.</em> at 1147.</p>
<p>However,  what is noticeably absent from the Ninth Circuit’s opinion is a discussion of the  preliminary issue that has become a focal point of the briefs and oral argument  before the Supreme Court: whether the compliance order is considered “final  agency action” sufficient to trigger review under the APA. </p>
<ol start="5" type="I">
<li><u>The Parties       Positions Regarding Final Agency Action Before the Supreme Court</u></li>
</ol>
<ol type="A">
<ol type="A">
<li><u>The  Merit Briefs</u></li>
</ol>
</ol>
<p>In  accepting certiorari, the Supreme Court asked the parties to address two  questions: 1) Whether the Sacketts may “seek pre-enforcement judicial review of  the Administrative Compliance Order pursuant to the Administrative Procedure  Act 5 U.S.C. § 704;” and 2) if not, does the Sacketts’ “inability to seek  pre-enforcement judicial review of the Administrative Compliance Order violate  their rights under the Due Process Clause?” <em>See </em><a href="http://www.americanbar.org/content/dam/aba/publishing/previewbriefs/Other_Brief_Updates/10-1062_petitioner.authcheckdam.pdf"  target="_blank"><strong>Brief for the  Petitioners</strong></a>, <em>Sackett v.  United States Environmental Protection Agency</em>, at i (No. 10-1062). In order  to fully answer these questions, the issue of whether the Administrative  Compliance Order constitutes “final agency action” is of critical importance.</p>
<p>In  their Initial Brief, the Sacketts, most likely because the Ninth Circuit  ignored the issue of whether the compliance order was a “final agency action,”  only briefly outline their position as to why the EPA’s compliance order qualifies  as “final agency action.” First, the Sacketts argue that the compliance order  “represents the consummation of the EPA’s decision-making process” for three  reasons: 1) “there are no further steps for the agency to take with respect to  jurisdiction, or with respect to the order’s issuance;” 2) “the order does not initiate  any administrative process, nor is there any administrative process whereby the  Sacketts can seek review of the order;” and 3) the CWA provides that the  compliance order is immediately enforceable in court by the agency. <em>See</em> Brief for the Petitioners, at 55.  Second, the Sacketts argue that the compliance order satisfies the second step  of the <em>Bennett</em> test because failure  to comply with the compliance order itself is both actionable and punishable by  civil penalties. Thus, according to the Sacketts, independent “legal  consequences flow from the compliance order.” <em>Id.</em></p>
<p> In  response, the Government dedicated several pages of its brief to counter the  Sacketts claims that the compliance order is a “final agency action” subject to  judicial review and argued that the compliance order fails both prongs of the <em>Bennett </em>test. First, the Government  argued that the compliance order fails step one of <em>Bennett</em> because it does not mark the consummation of the agency’s decision-making  process. According to the Government, the order invited the Sacketts to contact  the EPA informally regarding the terms and requirements of the order itself as  well as any factual allegations that the Sacketts believed to be false.  Additionally, the compliance order invited the Sacketts to propose alternatives  to the remediation plan proposed. Thus, “because EPA indicated that allegations  and conclusions underlying the order were subject to revision based on  petitioners might provide, and that the prescribed corrective measures were  subject to negotiation, the compliance order cannot properly be viewed as  representing the agency’s final conclusions.” <a href="http://www.justice.gov/osg/briefs/2011/3mer/2mer/2010-1062.mer.aa.pdf" target="_blank"><strong>Brief for the  Respondent</strong></a>, <em>Sackett v.  United States Environmental Protection Agency</em>, 24-25 (No. 10-1062). </p>
<p>The  Government also argued that the compliance order failed step two of <em>Bennett</em> because compliance orders merely  “express the agency’s views of what the law requires” and any factual  determinations made within the compliance order would be given no deference by  a court in an enforcement action. Brief for the Respondent, at 28. The Government  also argued that any potential legal consequences faced by the issuance of a  compliance order are not “sufficiently concrete or substantial to render the  order ‘final agency action.’” <em>Id.</em> at  29. Here, the Government’s argument mirrors the Ninth Circuit’s logic that  because the penalties associated with the failure to comply are subject to  judicial, not agency discretion, and because an after-the-fact permit process  exists which provides for judicial review wherein a potential violator can  challenge EPA jurisdiction, the legal consequences are not such that  pre-enforcement review is essential. <em>Id</em>.  at 29-31.</p>
<p>The  Sacketts countered the Government’s arguments in their Reply Brief arguing that <em>Bennett</em> is satisfied for several  reasons. First, the language of the CWA itself only permits a compliance order  to be issued <em>after</em> the EPA has made  findings that the CWA has been violated. <a href="http://sblog.s3.amazonaws.com/wp-content/uploads/2012/01/Sackett-Reply.pdf" target="_blank"><strong>Reply Brief for the  Petitioners</strong></a>, <em>Sackett v.  United States Environmental Protection Agency</em>, 13 (No. 10-1062).  Further, the CWA “makes clear that the  issuance of the compliance order is one of two equal <em>enforcement</em> options that EPA may take once it ‘finds’ that the  statute has been violated.” <em>Id.</em> at 16  (emphasis in original). Thus, “the compliance order is not a prelude to  enforcement[,] [r]ather, the compliance order <em>is </em>enforcement.” <em>Id</em>.  (emphasis in original). Next, the Sacketts cited numerous circuit court  decisions which have found that agency actions can be deemed “final” even  though the actions themselves provide for informal consultation between the  agency and an effected party. <em>Id. </em>at  15-16. Finally, the Sacketts argued that because the compliance order subjects  them to additional penalties for non-compliance and creates additional  requirements that must be satisfied <em>before</em> obtaining an after-the-fact permit, the compliance order creates additional  legal obligations sufficient to be considered final.</p>
<ol type="A">
<ol type="A" start="2">
<li><u>The  Government’s Policy Rationale for Arguing that Compliance Orders are Non-Final  Agency Action and Thus Not Entitled to the Presumption of Reviewability</u></li>
</ol>
</ol>
<p>In  addition to arguing in its brief that the compliance order failed to meet the <em>Bennett </em>test, the Government also  presented several policy-based arguments as to why compliance orders should not  be viewed as “final agency actions.”</p>
<p>The  Government argues that compliance orders: 1) inform parties regulated by the  administrative agency of requirements imposed by law, and 2) warn parties that  the failure to comply with such laws may result in future enforcement actions. <em>See</em> Brief of Respondents, at 14. Contrary  to the claims of the Sacketts, the Government’s position is that no additional  obligations are imposed on parties issued compliance orders. Rather, such  orders “set forth the EPA’s views as to the steps particular persons must take  to achieve prospective compliance with the CWA itself.” <em>Id.</em> at 17. </p>
<p>            Additionally,  the Government argues that compliance orders, as well as similar devices used  by other agencies, serve an important purpose of “obviate[ing] the need for  judicial intervention, either by inducing voluntary implementation of the  measures specified therein, or by triggering a process of consultation between  the agency and the alleged violator that produces a mutually acceptable  alternative resolution.” <em>Id.</em> at 13. The  Government further argues that communications such as compliance orders or  warning letters provide a benefit similar to that found in settings where  administrative exhaustion is required because agencies are given the  “opportunity to correct their own mistakes and to refine their views without  the need for judicial intervention.” <em>Id.</em> at 22. </p>
<p>  The  Government’s position is that compliance orders are neither entitled to  pre-enforcement review nor unlawful merely because they present the “Hobson’s  choice” of complying with an agency with questionable jurisdiction demands or  do nothing and wait to challenge the agency’s jurisdiction in an agency brought  enforcement order the face of mounting penalties. <em>Id.</em> at 22. Instead, the Government argues that “from the regulated  party’s perspective, such communications give recipients an opportunity to conform  their conduct to the agencies guidance before being subjected to an enforcement  action.” <em>Id.</em></p>
<p>            Given  the broad purposes of environmental regulation in general and the CWA in  particular, compliance orders allow the agency to achieve a quicker resolution  to situations of ongoing environmental damages. The Government believes that if  pre-enforcement judicial review is allowed for these communications their  effectiveness at achieving voluntary compliance would be substantially weakened  and resources of the administrative agency would be drained in litigating cases  of minor offenders. Thus, by preventing pre-enforcement judicial review and by  allowing agencies to “interact[] with regulated entities outside of more formal  administrative-adjudication or judicial-enforcement settings, agencies can  conserve resources and prioritize their enforcement efforts to respond to the  most sever violations.” <em>Id. </em>at 22.</p>
<ol>
<ol type="A" start="3">
<li><u>The  Court’s Questioning of the Government’s Position at Oral Argument</u></li>
</ol>
</ol>
<p>At  oral argument, the Justices focused on whether, based on <em>Abbott Laboratories</em> and the presumption of reviewability,  challenges to the jurisdiction of an agency issuance of a compliance order  require pre-enforcement review. In their questioning, the Justices appeared to  clearly distinguish between warning letters, which have long been considered  non-final agency action and not entitled to judicial review, and the compliance  orders issued by the EPA. In particular, the Justices appeared interested in  the language of the compliance order itself and the back and forth between the  agency and the alleged violator before and after the issuance of a compliance  order. Additionally, the Justices focused on the “Hobson’s choice” of either  voluntarily complying with an order that the issuing agency may not have the  jurisdiction to issue or to not comply, face mounting fines, and wait to assert  a jurisdictional challenge at some undetermined time as the agency so chooses  to bring an enforcement action. <a href="http://www.supremecourt.gov/oral_arguments/argument_transcripts/10-1062.pdf" target="_blank"><strong>Transcript of Oral  Argument</strong></a>, at 42-53, <em>Sackett  v. Environmental Protection Agency</em>, (No. 10-1062).</p>
<p>During  oral argument, Justice Breyer’s main concern as to whether the compliance order  could be considered non-final turned on the language in the order suggesting  that alleged violators should contact the EPA in informal discussions regarding  the terms and requirements of the order itself as well as any factual  allegations that the Sacketts believed to be false. In particular, Justice  Breyer appeared concerned with whether such post-issuance communications  actually result in the agency changing its position:</p>
<blockquote>
<p><strong>Justice  Breyer</strong>: Is there anything you’ve got by – I mean, I’m – You’ve got me now  into the area, we are applying the APA and the question is <em>Abbott Labs</em> and is it final. Well, here there doesn’t seem anything  more for the agency to do, and here the person who the order is directed  against is being hurt a lot. So the only thing I – left in my mind here is the order  itself does say: Come in and talk to us about this. Which may suggest it isn’t  final. So do you have any information on that point? That is, have you looked  up or has the APA told you that really when we issue these things, people come  in and modify them at X percent of the time.</p>
</blockquote>
<p><em>Id.</em> at 45 ln. 9-21. In response the Government argued that although  only 3 percent of all compliance orders ever lead to enforcement actions being  taken, the Government did not have any statistics as to whether this was because  of informal communications between the alleged violator and the agency or  whether it was merely because alleged violators have chosen to voluntarily comply. <em>Id.</em> at 46. </p>
<p>However,  when pressed by Justice Kagan as to whether post-issuance communications  normally result in modifications, the Government conceded that it was unlikely:</p>
<blockquote>
<p><strong>Justice  Kagan</strong>: Mr. Stewart, you suggested that, that some communication occurs  before this compliance order [is issued]. And my guess would be that most of  the back and forth between the agency and the person does happen before the  compliance order rather than after.</p>
<p>    And the notion that the person can  come in after the compliance order and say you were wrong, well they can, but  they can do that with respect to any administrative action. So, am I wrong  about that? That really the back and forth here takes place before the  compliance order issues rather than after?</p>
<p><strong>Mr.  Stewart</strong>: I think you are right as a matter of typical agency practice that  there would be an invitation well before the compliance order was issued to  come in and give your side of the story, and you are probably right that if we  got to the point where a compliance order was issued, then the likelihood that  further communications would sway the agency substantially might be reduced. So  I would take your point there –</p>
</blockquote>
<p><em>Id.</em> at 46 ln 15-25 – 47 ln. 1-10.</p>
<p>Of  particular note was the exchange between Justice Scalia and the Government  regarding the jurisdictional challenges to compliance orders. During the Government’s  argument Justice Scalia posed the question of whether a person can “usually  obtain a declaratory judgment if prosecution is threatened and you think that  there is no basis for it, and you can’t – you are not – you’re not compelled to  just stand there and wait for the prosecutor to, to drop the hammer?” <em>Id.</em> at 48.  In response, the Government argued that,  although declaratory judgment actions are available in such situations, because  the Government’s position is that compliance orders are “informal warnings,” extending  a right to a declaratory judgment to compliance orders “would cause a huge  upheaval in the practices of many agencies. . . .” <em>Id</em>. at 49. </p>
<p>However,  the Justices appeared to reject this rationale and further pressed the issue of  whether a compliance order should be considered “final agency action” with  Justice Breyer commenting: “You are talking about a huge upheaval. My honest  impression is that it is the Government here that is fighting 75 years of  practice because – because the issue is the <em>Abbott  Labs</em> issue of finality. And of course a warning isn’t reviewable. But this  seems to meet the test where that fails.” <em>Id. </em>at 49 ln. 19-23.</p>
<ol start="6" type="I">
<li><u>Analysis       and Conclusion</u></li>
</ol>
<p>Based  upon the totality of information before the Court, the arguments made by the  Sacketts that compliance orders are “final agency action” entitled to  pre-enforcement review appears to be strong. The Court pressed the Government  on the issue of whether post-issuance discussions between alleged violators and  the agency actually effect a change of the agency’s position. Additionally, the  Government conceded in both its brief and at oral argument that the failure of  alleged violators of the CWA to follow the remediation plan outlined in a  compliance order potentially subjects the violator to additional penalties  above and beyond the penalties for violating the CWA itself. </p>
<p>Moreover,  it appears that the Government’s strongest argument that compliance orders are  not entitled to pre-enforcement review is the “huge upheaval” such a ruling would  level on the day-to-day operations of administrative agencies. As explained  above, the Government has argued that a decision which classifies compliance  orders as “final” could result in increased litigation and decreased voluntary  compliance with the result being a more litigious and less effective  administrative state.</p>
<p>However,  even if the Court does agree with the Sacketts and finds that compliance order  are in fact “final” thus entitling recipients to pre-enforcement judicial  review, the practical consequences will not likely be as harsh as the Government  fears. First, the Court in oral argument appears to have reaffirmed that less  formal communications such as warning letters are properly considered non-final  agency action to which no pre-enforcement review is required. Other agencies  successfully use warning letters to achieve the same goals of voluntary  compliance and administrative efficiency. Additionally, despite the actual and incidental  consequences which commonly plague recipients who must defend themselves  against such letters, the Court consistently denies pre-enforcement review for  such agency actions. Furthermore, the Sacketts have not challenged any such  less formal actions. </p>
<p>Additionally,  the CWA provides for other forms of enforcement for violations, such as a civil  enforcement action without the issuance of a compliance order. Thus, should the  Supreme Court find that compliance orders are “final,” the most likely  “upheaval” would be the seismic shift towards the increased use by agencies of  warning letters followed by civil enforcement actions in cases of noncompliance. </p>
<p>Moreover,  as explained above, judicial review of a “final agency action” pursuant to the  APA can always be expressly superseded by an agency’s enabling statute. As  such, should the Supreme Court decide favorably for the Sacketts, and mark a  trend towards easier access to judicial review of agency actions, there is no  reason to think that federal administrative agencies would not lobby Congress  for statutory reforms to expressly preclude judicial review of compliance  orders.</p>
<p>The  debate as to what exactly is “final agency action” has been ongoing for decades.  However, until such a time that the Court is willing to take a more concrete  and expansive view of what qualifies under <em>Abbott  Laboratories</em> and <em>Bennett</em> as  “final agency action,” particularly a view based on the real life and practical  consequences of the issuance of warning letters, administrative law  practitioners, and their clients, will continue to be faced with a Hobson’s  choice and uncertainty when responding to such non-final actions. In the end,  the Court’s ultimate decision as to whether a compliance order is considered  “final agency action” which entitles recipients to pre-enforcement judicial  review may be more of a moral victory for administrative law attorneys and less  of a game-changer in litigation against federal agencies.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/31/sackett-v-epa-highlights-the-ongoing-debate-over-what-actions-are-final-agency-actions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patient Protection and Affordable Care Act Challenges Often Turn On Interpretation of the Court’s Commerce Clause Jurisprudence</title>
		<link>http://www.fuerstlaw.com/wp/index.php/20/patient-protection-and-affordable-care-act-challenges-often-turn-on-interpretation-of-the-courts-commerce-clause-jurisprudence/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/20/patient-protection-and-affordable-care-act-challenges-often-turn-on-interpretation-of-the-courts-commerce-clause-jurisprudence/#comments</comments>
		<pubDate>Tue, 20 Sep 2011 15:02:59 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[General]]></category>
		<category><![CDATA[Litigation]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=1500</guid>
		<description><![CDATA[On  September 13, 2011, the United States District Court for the Middle District of  Pennsylvania issued its decision finding that the individual mandate provision  of the Patient Protection and Affordable Care Act (PPACA) exceeded Congress’s authority under the Commerce Clause and therefore  is unconstitutional. As discussed in a recent Forbes article, [...]]]></description>
			<content:encoded><![CDATA[<p>On  September 13, 2011, the United States District Court for the Middle District of  Pennsylvania issued its decision finding that the individual mandate provision  of the <a href="http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf" target="_blank"><strong>Patient Protection and Affordable Care Act</strong></a> (PPACA) exceeded Congress’s authority under the Commerce Clause and therefore  is unconstitutional. As discussed in a recent Forbes article, this decision is  merely one in a long line of District and Circuit opinions on the  constitutionality of the PPACA. Ultimately, the individual mandate provision  the PPACA’s constitutionality will turn on the interpretation of two bedrocks  of Commerce Clause precedent, <a href="http://supreme.justia.com/us/317/111/case.html" target="_blank"><strong>Wickard v. Filburn</strong></a>, 317 U.S. 111 (1942)  and <a href="http://www.oyez.org/cases/2000-2009/2004/2004_03_1454/" target="_blank"><strong>Gonzales v. Raich</strong></a>, 545 U.S. 1 (2005). A  copy of the Forbes article can be read <a href="http://www.forbes.com/sites/danielfisher/2011/09/14/obamacares-fate-rests-with-poor-farmer-filburn/" target="_blank"><strong>here.</strong></a></p>
<p>Generally speaking, Congress’s power  under the Commerce Clause extends to three broad categories. First, Congress  may regulate the channels of interstate commerce. Second, Congress may regulate  and protect the instrumentalities of interstate commerce. Finally, Congress may  regulate activities that have a substantial effect on interstate commerce. <em>See</em> <a href="http://www.law.cornell.edu/supct/html/93-1260.ZO.html" target="_blank"><strong>United States v. Lopez</strong></a>, 514 U.S. 549,  558 (1995). It is within this third category that Congress’s Commerce Clause  authority is pressed to its “outer limits” and is often the subject of judicial  challenge. <em>See</em> <em>Id.</em> at 557. Such is the case with the PPACA. </p>
<p> In <em>Wickard</em>, the Supreme Court held that Congress could regulate the  production of home grown wheat meant solely for personal use under its Commerce  Clause power. In so holding, the Court found that although Filburn’s activities  were entirely local, such activities, when taken in the aggregate, had a  substantial effect on the national market for wheat. In the annals of Commerce  Clause jurisprudence, <em>Wickard v. Filburn</em> represents the high-water mark for Congressional power.</p>
<p> More than 60 years later,    in <em>Gonzales  v. Raich</em>, the Supreme Court upheld Congress’s authority under the Commerce  Clause to prohibit the possession of home-grown marijuana intended solely for  personal use, even when such possession was allowed by state law. Similar to  the Court’s rationale in <em>Wickard</em>, the <em>Raich</em> Court found that the production  of marijuana substantially affects supply and demand in the national market;  therefore the regulation was “squarely within Congress’ commerce power.” The  Court went on to hold that “Congress can regulate purely intrastate activity  that is not itself ‘commercial’ . . . if it concludes that failure to regulate  that class of activity would undercut the regulation of the interstate market  in that commodity.” <em>Raich</em>, at 18.  Both <em>Raich </em>and <em>Wickard</em> stand for an expansive and broad reading of Congress’s  power under the Commerce Clause. </p>
<p>In finding that the PPACA’s  individual mandate was unconstitutional, Judge Conner distinguished the mandate  from the economic regulations at issue in <em>Wickard</em> and <em>Raich</em>. The Court found that  unlike the laws at issue in <em>Wickard </em> and <em>Raich</em>,  which allowed people to not engage in regulated conduct and thereby stay beyond  the reach of the statute, PPACA’s mandate <em>requires</em> people to become active participants in the health insurance market regardless  of whether heath services will be used. As explained by Judge Conner:</p>
<p>Congress can reach the personal  production of wheat – a clear activity affecting the interstate market – in an  effort to stabilize the wheat market. Congress cannot, however, in order to  stabilize that market, force the purchase of wheat by individuals who decide to  forego wheat or wheat products, even if Congress legitimately determines that  an individual’s decision not to purchase wheat or wheat products inhibits the  government’s ability to regulate or stabilize the wheat market. Similarly,  Congress may lawfully regulate the interstate market for health insurance and  health services, but Congress cannot require individuals who choose not to  purchase health insurance or individuals who are not currently seeking or  receiving services in the health care market to purchase health insurance in  order to stabilize the health insurance market. Congress cannot mandate or  regulate in anticipation of conduct that may or may not occur.</p>
<p><em><a href="http://plf.typepad.com/ObamacareAC/Goudy-Bachman2.pdf" target="_blank"><strong>Bachman v. U.S. Department of Health and Human Service,  et. al.</strong><strong>, at 36</strong><strong>.</strong></a></em></p>
<p>The Court went on to find that an  uninsured individual’s conduct has no effect on conduct Congress sought to  regulate under the Commerce Clause until such time that: 1) the individual  obtains health care services; and 2) the individual does not pay for the  services received. The Court stated that “the mere status of being without  health insurance, in and of itself, has absolutely no impact on interstate  commerce . . . at least not any more so than the status of being without any  particular good or service.” <em>Id.</em> at  38. As a result, “current Commerce Clause precedent does not permit Congress to  reach a pre-transaction stage in anticipation of participation in a market. . .  .”<em>Id.</em> at 40.</p>
<p>Ultimately, it is likely that the  final decision as to the constitutionality of the individual mandate of the  PPACA will be made by the Supreme Court. Such a decision has the potential to  reshape Congress’s power to regulate individuals and businesses under the  Commerce Clause regardless of its outcome. Fuerst Ittleman will continue to  monitor the litigation challenging the PPACA and its effects on Commerce Clause  jurisprudence. For more information, please contact us at <a href="mailto:contact@fuerstlaw.com" target="_blank"><strong>contact@fuerstlaw.com</strong></a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/20/patient-protection-and-affordable-care-act-challenges-often-turn-on-interpretation-of-the-courts-commerce-clause-jurisprudence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>USDA Proposes Mandatory Livestock Tracking System</title>
		<link>http://www.fuerstlaw.com/wp/index.php/17/usda-proposes-mandatory-livestock-tracking-system/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/17/usda-proposes-mandatory-livestock-tracking-system/#comments</comments>
		<pubDate>Wed, 17 Aug 2011 14:25:26 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[FDA]]></category>
		<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=1446</guid>
		<description><![CDATA[On August 9, 2011, the U.S. Department  of Agriculture’s (USDA) Animal and Plant Health Inspection  Service (APHIS) issued a proposed rule to establish a mandatory  livestock tracking system in order to improve the traceability of U.S.  livestock. The proposed rule would require farmers and ranchers to affix unique  identification numbers [...]]]></description>
			<content:encoded><![CDATA[<p>On August 9, 2011, the U.S. Department  of Agriculture’s (<a href="http://www.usda.gov/wps/portal/usda/usdahome" target="_blank">USDA</a>) Animal and Plant Health Inspection  Service (<a href="http://www.aphis.usda.gov/" target="_blank">APHIS</a>) <a href="http://www.regulations.gov/#!documentDetail;D=APHIS-2009-0091-0001" target="_blank">issued a proposed rule</a> to establish a mandatory  livestock tracking system in order to improve the traceability of U.S.  livestock. The proposed rule would require farmers and ranchers to affix unique  identification numbers to animals transported interstate. The rule seeks to  establish an effective, transparent animal disease traceability system without  additional burden on farmers and ranchers. The tracking system would allow  federal officials to quickly isolate diseased animals in the event of an  outbreak. </p>
<p>In 2004, the USDA began developing a  framework for animal disease traceability through the implementation of the National  Animal Identification System (<a href="http://www.aphis.usda.gov/traceability/" target="_blank">NAIS</a>). NAIS  is a voluntary registration system established to trace the source of an animal  disease within 48 hours. However, in 2009, the USDA estimated that only 36  percent of farmers and ranchers participated in the NAIS. In order to improve  traceability, APHIS launched a series of efforts to assess the acceptance of an  animal disease traceability system which lead to the development of the  proposed rule.   </p>
<p>The proposed rule requires that livestock  moved interstate be officially identified and accompanied by an interstate  certificate of veterinary inspection or other documentation, such as  owner-shipper statements or brand certificates, unless exempt. Official forms  of identification include tattoos, metal eartags, or brands with certain  exceptions. The proposed rule also allows for States and tribes to develop  alternative forms of identification. Livestock subject to the identification requirements  include cattle, bison, sheep, goats, swine, horses, captive cervids, and  poultry.</p>
<p>The USDA is confident that the new  system will be able to trace the source of an animal disease within a few days  of an outbreak. Advocates say the implementation of the new mandatory system  would be a significant improvement compared to USDA bovine tuberculosis  investigations averaging 150-days to trace the source of an outbreak.  </p>
<p>The USDA is currently seeking <a href="http://www.regulations.gov/#!submitComment;D=APHIS-2009-0091-0001" target="_blank">public comment</a> on the proposed rule for a  mandatory livestock tracking system. The deadline for submission is November 9,  2011. Fuerst Ittleman will continue to monitor the development of the USDA APHIS’s  new proposed rule. For more information, please contact us at <a href="mailto:contact@fuerstlaw.com" target="_blank">contact@fuerstlaw.com</a>. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/17/usda-proposes-mandatory-livestock-tracking-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Johnson &amp; Johnson Seeks Settlement in for Allegations of Off-Label Promotion of Risperdal</title>
		<link>http://www.fuerstlaw.com/wp/index.php/17/johnson-johnson-seeks-settlement-in-for-allegations-of-off-label-promotion-of-risperdal/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/17/johnson-johnson-seeks-settlement-in-for-allegations-of-off-label-promotion-of-risperdal/#comments</comments>
		<pubDate>Wed, 17 Aug 2011 14:23:03 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[FDA]]></category>
		<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=1444</guid>
		<description><![CDATA[In 2004, the U.S.  Department of Justice (DOJ) Office of the Inspector General (OIG) began investigating Janssen  Pharmaceutica Inc. (Janssen), a subsidiary of Johnson &#38;  Johnson (J&#38;J),  concerning the marketing practices for Risperdal, an antipsychotic prescription  drug. Janssen allegedly promoted Risperdal for unapproved off-label uses, a  misdemeanor criminal offense. [...]]]></description>
			<content:encoded><![CDATA[<p>In 2004, the U.S.  Department of Justice (<a href="http://www.justice.gov/" target="_blank">DOJ</a>) Office of the Inspector General (<a href="http://www.justice.gov/oig/"target="_blank">OIG</a>) began investigating Janssen  Pharmaceutica Inc. (<a href="http://www.janssenpharmaceuticalsinc.com/"target="_blank">Janssen</a>), a subsidiary of Johnson &amp;  Johnson (<a href="http://www.jnj.com/connect/"target="_blank">J&amp;J</a>),  concerning the marketing practices for Risperdal, an antipsychotic prescription  drug. Janssen allegedly promoted Risperdal for unapproved off-label uses, a  misdemeanor criminal offense. Pursuant to the Federal Food, Drug, and Cosmetic  Act (<a href="http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/default.htm"target="_blank">FD&amp;C Act</a>) manufacturers are prohibited from  directly marketing a drug for a use other than the U.S. Food and Drug  Administration (<a href="http://www.fda.gov/default.htm"target="_blank">FDA</a>) approved indication. 21 U.S.C. §§301-97. The FDA  approved Risperdal for the treatment of schizophrenia in <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails"target="_blank">adults</a> and <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108969.htm"target="_blank">adolescents</a>. Allegations suggest that Janssen also  promoted Risperdal for the treatment of dementia and anxiety disorders. See our  previous report <a href="http://www.fuerstlaw.com/wp/index.php/14/fda-message-to-pharma-misdemeanor-criminal-charges-can-result-from-promoting-off-label-drug-uses/"target="_blank">here</a> for more information regarding misdemeanor criminal  charges resulting from off-label promotion.</p>
<p>On August, 9, 2011, in  a <a href="http://www.investor.jnj.com/secfiling.cfm?filingID=950123-11-75098"target="_blank">quarterly report</a> filed with the Securities and  Exchange Commission (<a href="http://www.sec.gov/"target="_blank">SEC</a>), J&amp;J announced efforts to resolve the criminal  penalties related to Risperdal marketing. J&amp;J stated that an agreement had  been reached with the DOJ regarding the key issues; however, the settlement has  yet to be finalized. J&amp;J adjusted its financial statements for the second  quarter of 2011 to reflect the financial component of the proposed criminal  settlement.  </p>
<p>In addition, J&amp;J  announced the settlement of a tolling agreement with approximately 40 states.  The tolling agreement allows for the delay of the statute of limitations in  order to provide J&amp;J an opportunity negotiate civil claims with states  before a state is forced to file a complaint to preserve their rights. J&amp;J states  litigation is likely if negotiated resolutions cannot be reached in regards to  the civil litigation relating to the allegations of off-label promotion of Risperdal.  Pursuant to the False Claims Act, companies who knowingly represent a false  approval are subject to civil penalties. <a href="http://www.law.cornell.edu/uscode/31/usc_sec_31_00003729----000-.html"target="_blank">31 U.S.C. § 3729</a>.  </p>
<p>J&amp;J claims that the  resolution of the criminal and civil matters is not expected to have a material  adverse effect on the Company’s financial position, although the resolution in  any reporting period could have a material impact on the Company’s results of  operations and cash flows for that period.</p>
<p>For more information  regarding the drug approval process or for any questions regarding how your  company can maintain regulatory compliance, please contact us at <a href="mailto:contact@fuerstlaw.com"target="_blank">contact@fuerstlaw.com</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/17/johnson-johnson-seeks-settlement-in-for-allegations-of-off-label-promotion-of-risperdal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Issues Guidance Clarifying When Changes or  Modifications to an Existing 510(k) Require New PMA Submission</title>
		<link>http://www.fuerstlaw.com/wp/index.php/28/fda-issues-guidance-clarifying-when-changes-or-modifications-to-an-existing-510k-require-new-pma-submission/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/28/fda-issues-guidance-clarifying-when-changes-or-modifications-to-an-existing-510k-require-new-pma-submission/#comments</comments>
		<pubDate>Thu, 28 Jul 2011 21:06:51 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=1368</guid>
		<description><![CDATA[On  July 26, 2011, the U.S. Food and Drug Administration (FDA) <a href="http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM265349.pdf" target="_blank">issued</a> draft guidance that  clarifies when changes or modifications to a previously cleared 510(k) device  necessitate a new premarket submission. In order to introduce a medical device  into the interstate market, the FDA must either approve a premarket application  (PMA) or clear a 510(k) premarket notification. ]]></description>
			<content:encoded><![CDATA[<p>On  July 26, 2011, the U.S. Food and Drug Administration (FDA) <a href="http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM265349.pdf" target="_blank">issued</a> draft guidance that  clarifies when changes or modifications to a previously cleared 510(k) device  necessitate a new premarket submission. In order to introduce a medical device  into the interstate market, the FDA must either approve a premarket application  (PMA) or clear a 510(k) premarket notification. Lower-risk devices are often  submitted through the 510(k) premarket notification process, whereby the FDA  “clears” the device for sale if it is found to be substantially equivalent to a  previously cleared predicate device. The FDA <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm265458.htm" target="_blank">announced</a> that an additional  510(k) notification is required in instances where a change or modification to  a cleared device would “significantly affect the product’s safety or  effectiveness” or “constitute a major change to the intended use of the  device.” </p>
<p>The new draft guidance outlines when  an additional 510(k) notification is required for compliance with FDA  regulations. The guidance suggests that manufacturers should compare the  modified device to the most recently cleared version of the device to determine  whether the modification could significantly affect its safety or  effectiveness. In addition, manufacturers should assess individual changes to a  device to determine whether, if at all, any of those  changes constitutes a major change to the product’s safety, effectiveness, or  intended use. A manufacturer should clearly document whether it believes the  change does or does not require submission of an additional 510(k)  notification, as well as the reason for that decision.</p>
<p> Furthermore, the FDA provides  specific guidance to help manufacturers determine whether to submit an  additional 510(k) notification for changes or modifications to the  manufacturing process, product labeling, technology or engineering, or material  type. This guidance also instructs manufacturers to weigh whether bench testing  or simulations are sufficient to assess the safety or effectiveness of a  modified device. Absent clear evidence of safety or effectiveness from these  types of testing, the FDA suggests that manufacturers conduct clinical data  using human subjects to validate the safety of these products. </p>
<p>This  guidance document is part of the FDA’s Plan of Action for Implementation of  510(k) and Science Recommendations, a series of action items launched earlier  this year intended to “enhance predictability, consistency, and transparency of  the FDA’s premarket review programs.” For more information about the FDA’s Plan  of Action, see our previous post <a href="http://www.fuerstlaw.com/wp/index.php/25/fda-begins-overhaul-of-510k-process/" target="_blank">here</a>.</p>
<p>Fuerst  Ittleman is well-equipped to assist members of FDA-regulated industry navigate  the laws and regulations applicable to medical devices. For more information  about the current regulatory framework surrounding medical devices, please  contact us at <a href="mailto:contact@fuerstlaw.com" target="_blank">contact@fuerstlaw.com</a>. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/28/fda-issues-guidance-clarifying-when-changes-or-modifications-to-an-existing-510k-require-new-pma-submission/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Whistleblowers Claim Dialysis Company Deliberately Wasted Hundreds of Millions of Dollars in Medicine to Collect Medicare Overpayment</title>
		<link>http://www.fuerstlaw.com/wp/index.php/28/whistleblowers-claim-dialysis-company-deliberately-wasted-hundreds-of-millions-of-dollars-in-medicine-to-collect-medicare-overpayment/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/28/whistleblowers-claim-dialysis-company-deliberately-wasted-hundreds-of-millions-of-dollars-in-medicine-to-collect-medicare-overpayment/#comments</comments>
		<pubDate>Thu, 28 Jul 2011 21:03:12 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=1366</guid>
		<description><![CDATA[<p>Earlier  this week, a pair of whistleblowers filed an <a href="http://www.whetriallaw.com/downloads/DAVITA_COMPLAINT.pdf" target="_blank">amended complaint</a> in United States  District Court in Atlanta alleging that DaVita, a kidney dialysis clinic,  intentionally wasted medicine to collect Medicare drug overpayments. The plaintiffs  claim that DaVita changed how it dispensed dialysis medication in order to inflate  their Medicare reimbursement return.<strong> </strong>The  original complaint, which was filed in October of 2007, was unsealed this past  week. After two years of investigating the claim, the federal government  decided in April that it did not intend to join the lawsuit. </p>]]></description>
			<content:encoded><![CDATA[<p>Earlier  this week, a pair of whistleblowers filed an <a href="http://www.whetriallaw.com/downloads/DAVITA_COMPLAINT.pdf" target="_blank">amended complaint</a> in United States  District Court in Atlanta alleging that DaVita, a kidney dialysis clinic,  intentionally wasted medicine to collect Medicare drug overpayments. The plaintiffs  claim that DaVita changed how it dispensed dialysis medication in order to inflate  their Medicare reimbursement return.<strong> </strong>The  original complaint, which was filed in October of 2007, was unsealed this past  week. After two years of investigating the claim, the federal government  decided in April that it did not intend to join the lawsuit. </p>
<p>DaVita, the second largest  independent provider of dialysis services for patients with chronic kidney  failure, is responsible for treating nearly one-third of the nation’s dialysis  patients. The complaint against DaVita alleges that <a href="http://eon.businesswire.com/news/eon/20110726005910/en" target="_blank">the company designed  multiple sets of conflicting internal protocols and “dosing grids” that  dictated how each drug should be administered to patients, based on the cost of  the drug and Medicare reimbursement</a>. Prior to January 2011, Medicare paid  dialysis centers separately for dialysis procedures and medication. Dialysis  centers often made a profit from these Medicare reimbursements because Medicare  reimbursed more than the centers paid for the medicine. Earlier this year,  however, Medicare changed its payment plan in an attempt to curb overuse of  dialysis drugs. In January, Medicare transitioned to a bundled-payment system,  where payments are fixed per treatment and include the cost of drugs. Under  this system, Medicare reimburses dialysis centers for the total amount of  medicine contained in the vial, not the amount of medicine administered to the  patient</p>
<p>In response to this new reimbursement  system, DaVita adjusted the way it ordered and administered medication. Under  the old system, for example, DaVita’s dialysis treatment consisted of a  six-microgram dose, which was administered in three vials of two-micrograms  each. After Medicare shifted to the bundled-payment system, DaVita used the  same six-microgram therapy program but administered the therapy from a single  10-microgram vial instead. According to the whistleblowers, the excess  four-micrograms were not used in therapy and were simply wasted. The dialysis  treatment remained the same, except DaVita charged Medicare for four extra  micrograms of medication it did not actually administer to patients. A similar  sequence of events was reported for DaVita’s administration of Venofer, where approximately  75 milligrams of medication was wasted each therapy session. These examples are  contrasted with DaVita’s use of Epogen, an anemia drug that is paid for based  on the amount actually used, not the amount per vial. The lawsuit alleges that DaVita  did not waste any Epogen medication. The allegations against DaVita have been  supported by other physicians and nurses working in dialysis clinics around the  nation. </p>
<p>DaVita denies that it overused pharmaceuticals in return for  financial incentives. A representative of DaVita claims that the changes in its  administration of dialysis therapy have been dictated by physicians, not  DaVita’s own drug protocol. </p>
<p>Fuerst Ittleman will continue to  monitor the progress of this whistleblower lawsuit For additional information,  please contact us at <a href="mailto:contact@fuerstlaw.com">contact@fuerstlaw.com</a>. </p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/28/whistleblowers-claim-dialysis-company-deliberately-wasted-hundreds-of-millions-of-dollars-in-medicine-to-collect-medicare-overpayment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Robert Becerra Presentation to National Assocation of Purchasing Management</title>
		<link>http://www.fuerstlaw.com/wp/index.php/01/robert-becerra-presentation-to-national-assocation-of-purchasing-management/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/01/robert-becerra-presentation-to-national-assocation-of-purchasing-management/#comments</comments>
		<pubDate>Fri, 01 Jul 2011 21:00:59 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=1302</guid>
		<description><![CDATA[On June 30, 2011, Fuerst Ittleman lawyer Robert Becerra gave a presentation on “Criminal Prosecution in the International Trade Arena: Conducting Business While Staying Out of Jail” to the National Association of Purchasing Management, South Florida Chapter and the Association of Operations Management.  The presentation was featured at the National Association of Purchasing Management’s [...]]]></description>
			<content:encoded><![CDATA[<p>On June 30, 2011, Fuerst Ittleman lawyer <a href="/our-firm/robert-j.-becerra%252c-esq.">Robert Becerra</a> gave a presentation on “Criminal Prosecution in the International Trade Arena: Conducting Business While Staying Out of Jail” to the National Association of Purchasing Management, South Florida Chapter and the Association of Operations Management.  The presentation was featured at the National Association of Purchasing Management’s installation dinner for its officers for the 2011-2012 year.  Robert Becerra concentrates his practice on white collar criminal defense, grand jury investigations, regulatory proceedings, civil forfeitures, corporate compliance and internal investigations, among other areas.  He is “AV” rated by the Martindale Hubbell Law Directory, rated a “Top Lawyer” by the South Florida Legal Guide, and as “Superb” by the lawyer rating website <a href="http://www.avvo.com">www.Avvo.com</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/01/robert-becerra-presentation-to-national-assocation-of-purchasing-management/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HCC Insurance Holdings, Inc. Reaches Settlement With OFAC Over Alleged Violations of Iranian Transactions Regulations.</title>
		<link>http://www.fuerstlaw.com/wp/index.php/27/hcc-insurance-holdings-inc-reaches-settlement-with-ofac-over-alleged-violations-of-iranian-transactions-regulations/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/27/hcc-insurance-holdings-inc-reaches-settlement-with-ofac-over-alleged-violations-of-iranian-transactions-regulations/#comments</comments>
		<pubDate>Wed, 27 Apr 2011 19:57:31 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=1088</guid>
		<description><![CDATA[On April 26, 2011, the Office of Foreign Assets Control (“OFAC”) of the U.S. Department of the Treasury announced that it had reached a settlement with HCC Insurance Holdings, Inc. (“HCC”) over alleged violations of the Iranian Transactions Regulations (“ITR”). The ITR, which are found at 31 C.F.R. part 560, were promulgated pursuant to the <a href="http://www.treasury.gov/resource-center/sanctions/Documents/ieepa.pdf">International Emergency Economic Powers Act</a> and are administered by OFAC. General information regarding economic sanctions against Iran can be found at OFAC’s website <a href="http://www.treasury.gov/resource-center/sanctions/Programs/Documents/iran.pdf">here</a>.]]></description>
			<content:encoded><![CDATA[<p>On April 26, 2011, the Office of Foreign Assets Control (“OFAC”) of the U.S. Department of the Treasury announced that it had reached a settlement with HCC Insurance Holdings, Inc. (“HCC”) over alleged violations of the Iranian Transactions Regulations (“ITR”). The ITR, which are found at 31 C.F.R. part 560, were promulgated pursuant to the <a href="http://www.treasury.gov/resource-center/sanctions/Documents/ieepa.pdf">International Emergency Economic Powers Act</a> and are administered by OFAC. General information regarding economic sanctions against Iran can be found at OFAC’s website <a href="http://www.treasury.gov/resource-center/sanctions/Programs/Documents/iran.pdf">here</a>.</p>
<p>The settlement agreement and alleged violations of the IRT highlight the breadth and complexity of the sanctions on trade with Iran. OFAC alleged that HCC, a wholly-owned insurance subsidiary of Houston Casualty Company, violated 31 C.F.R. §§ <a href="http://edocket.access.gpo.gov/cfr_2010/julqtr/31cfr560.206.htm">560.206</a> and <a href="http://edocket.access.gpo.gov/cfr_2010/julqtr/31cfr560.208.htm">560.208</a> of the IRT by participating in the hull portion of a hull and liability aviation insurance policy that covered commercial flights operating in Iran from April 2005 to April 2006. 31 C.F.R. § 560.206 prohibits U.S. persons from “financing, facilitating, or guaranteeing” goods, technology or services to Iran. Additionally, 31 C.F.R. § 560.208 prohibits U.S. persons from approving, financing, facilitating, or guaranteeing any transaction by a foreign person where the transaction performed would be prohibited under the IRT if performed by a U.S. person.</p>
<p>More specifically, OFAC alleged the violations occurred when: 1) a foreign insurance broker insured a foreign-owned commercial airline with a hull and liability policy of which HCC was a part; 2) the foreign-owned commercial airliner then leased aircraft covered by this policy to an air charter company that operated in Iran. As a result of this arraignment, HCC received $113,921 in premiums. HCC voluntarily disclosed the violation and OFAC announced that HCC paid $38,448 in penalties for its violations. According to OFAC enforcement guidelines, the base penalty associated with such a violation is $56,960. However, this penalty was lowered because HCC cooperated with OFAC in its investigation and it had not been subject to prior OFAC penalties or administrative actions. A copy of OFAC’s announcement can be read <a href="http://www.treasury.gov/resource-center/sanctions/CivPen/Documents/04262011.pdf">here</a>. </p>
<p>For more information regarding OFAC and strategies on maintaining compliance with federal regulations, please contact Fuerst Ittleman at 305-350-5690 or <a href="mailto:contact@fuerstlaw.com">contact@fuerstlaw.com</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/27/hcc-insurance-holdings-inc-reaches-settlement-with-ofac-over-alleged-violations-of-iranian-transactions-regulations/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court limits the Confrontation Clause of the Sixth Amendment in Michigan v. Bryant</title>
		<link>http://www.fuerstlaw.com/wp/index.php/07/supreme-court-limits-the-confrontation-clause-of-the-sixth-amendment-in-michigan-v-bryant/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/07/supreme-court-limits-the-confrontation-clause-of-the-sixth-amendment-in-michigan-v-bryant/#comments</comments>
		<pubDate>Mon, 07 Mar 2011 18:58:53 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=924</guid>
		<description><![CDATA[On February 28, 2011, in Michigan v. Byrant, Justice Sotomayor writing for the United States Supreme Court held that a victim’s identification and description of the defendant and the location of the alleged crime were not testimonial statements because they had a “primary purpose . ]]></description>
			<content:encoded><![CDATA[<p>On February 28, 2011, in Michigan v. Byrant, Justice Sotomayor writing for the United States Supreme Court held that a victim’s identification and description of the defendant and the location of the alleged crime were not testimonial statements because they had a “primary purpose . . . to enable police assistance to meet an on-going emergency.”  Citing Davis v. Washington, 547 U. S., at 822. Therefore, the use of the identification at the Defendant’s trial did not violate the Confrontation Clause.</p>
<p>To make the “primary purpose” determination, the a criminal court must objectively evaluate the circumstances in which the out-of-court statement was given to the police and the parties’ statements and actions. The primary purpose inquiry is an objective analysis.  The existence of an “ongoing emergency” at the time of the encounter is among the most important circumstances informing the interrogation’s “primary purpose.”</p>
<p>However Justice Scalia wrote a blistering dissent rejecting the majority&#8217;s opinion.  The highlights of the dissent include the following passages:</p>
<p>Today’s tale—a story of five officers conducting successive examinations of a dying man with the primary purpose, not of obtaining and preserving his testimony regarding his killer, but of protecting him, them, and others from a murderer somewhere on the loose—is so transparently false that professing to believe it demeans this institution. But reaching a patently incorrect conclusion on the facts is a relatively benign judicial mischief; it affects, after all, only the case at hand. In its vain attempt to make the incredible plausible, however—or perhaps as an intended second goal—today’s opinion distorts our Confrontation Clause jurisprudence and leaves it in a shambles. Instead of clarifying the law, the Court makes itself the obfuscator of last resort.</p>
<p>The only virtue of the Court’s approach (if it can be misnamed a virtue) is that it leaves judges free to reach the “fairest” result under the totality of the circumstances. If the dastardly police trick a declarant into giving an incriminating statement against a sympathetic defendant, a court can focus on the police’s intent and declare the statement testimonial. If the defendant “deserves” to go to jail, then a court can focus on whatever perspective is necessary to declare damning hearsay nontestimonial. And when all else fails, a court can mix-and-match perspectives to reach its desired outcome. Unfortunately, under this malleable approach “the guarantee of confrontation is no guarantee at all.”</p>
<p>The full opinion can be found here: <a href="http://www.supremecourt.gov/opinions/10pdf/09-150.pdf">http://www.supremecourt.gov/opinions/10pdf/09-150.pdf</a></p>
<p>The attorneys at Fuerst Ittleman have extensive experience handling white collar criminal cases at both the trial and the appellate level.  You can reach an attorney by emailing us at <a href="mailto:contact@fuerstlaw.com">contact@fuerstlaw.com</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/07/supreme-court-limits-the-confrontation-clause-of-the-sixth-amendment-in-michigan-v-bryant/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Final FASB Guidance on Troubled Debt Restructurings Due Out by March 31, 2011</title>
		<link>http://www.fuerstlaw.com/wp/index.php/01/final-fasb-guidance-on-troubled-debt-restructurings-due-out-by-march-31-2011/</link>
		<comments>http://www.fuerstlaw.com/wp/index.php/01/final-fasb-guidance-on-troubled-debt-restructurings-due-out-by-march-31-2011/#comments</comments>
		<pubDate>Tue, 01 Mar 2011 19:41:19 +0000</pubDate>
		<dc:creator>paperstreet</dc:creator>
				<category><![CDATA[General]]></category>

		<guid isPermaLink="false">http://www.fuerstlaw.com/wp/?p=909</guid>
		<description><![CDATA[At  its board meeting on February 23, 2011, the Financial Accounting Standards  Board (FASB) stated that it plans to issue its final guidance on Troubled Debt  Restructurings (TDRs) by March 31, 2011.
At  the present time there are no clear guidelines to assist creditors in  determining whether a loan or other [...]]]></description>
			<content:encoded><![CDATA[<p>At  its board meeting on February 23, 2011, the Financial Accounting Standards  Board (FASB) stated that it plans to issue its final guidance on Troubled Debt  Restructurings (TDRs) by March 31, 2011.</p>
<p>At  the present time there are no clear guidelines to assist creditors in  determining whether a loan or other debt modification meets the criteria to be  considered a TDR, both for debt recording and TDR disclosure purposes.  In announcing the guidance initiative last  year, FASB Acting Chairman Leslie Seidman stated that the guidance should &ldquo;result  in more consistent application of GAAP for debt restructurings.&rdquo;</p>
<p>On  the basis of public comments and Board deliberations to the guidance initiative,  FASB recommended earlier this year that the final guidance will feature:</p>
<ul style="list-style:none">
<li style="color:#000">a  specification that the absence of a market rate for a loan with risks similar  to the restructured loan is an <u>indicator</u> of a troubled debt  restructuring, but not a <u>determinative factor</u></li>
<li style="color:#000">>assessment  of whether a restructuring reaches the level of a TDR should consider all of  the modified terms of the restructuring, including any additional collateral or  guarantees</li>
<li style="color:#000">>insignificant  delays in cash flows are a factor to consider when determining whether a  concession has been granted</li>
<li style="color:#000">>for  purposes of determining whether a borrower is experiencing financial  difficulty, creditors should consider whether default is &ldquo;probable in the  foreseeable future.&rdquo;</li>
</ul>
<p>At  the February 23rd Board meeting, the FASB discussed many facets of TDRs  including a lengthy analysis of the concept of &ldquo;insignificant delays in cash  flows,&rdquo; in the context of restructurings.   The Board also discussed the transition provisions and effective date  for the new guidance.</p>
<p>With  respect to the latter issue, the FASB affirmed that the final guidance on TDRs  will be prepared by March 31 of this year.   The Board also stated that the interim guidance proposed in the <a href="http://www.fasb.org/cs/BlobServer?blobcol=urldata&amp;blobtable=MungoBlobs&amp;blobkey=id&amp;blobwhere=1175821471077&amp;blobheader=application%2Fpdf" target="_blank">October  13, 2010 Exposure Draft</a> would be effective on a prospective basis for  interim and annual periods ending after June 15, 2011, with retrospective  application permitted.  </p>
]]></content:encoded>
			<wfw:commentRss>http://www.fuerstlaw.com/wp/index.php/01/final-fasb-guidance-on-troubled-debt-restructurings-due-out-by-march-31-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

